| Name | Teriparatide acetate |
|---|---|
| Synonyms |
MFCD00149013
Teripatide, Pathyroid Hormone PTH (HUMAN, ) Teripatide (Forteo) Teripatide, Pathyroid Hormone,human Teripatide Acetate/pTH human SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-G-VAL-GLU-TRP-LEU-G-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE TeripatideAcetate impurity Pathyroid Hormone , Human - - Calbiochem Teripatide Acetate ptide Forteo Teripatide acetate/HuMan PTH Pathormone ALA-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ALA-SER-VAL-GLU-G-MET-GLN-TRP-LEU-G-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE: AVSEIQLMHNLGKHLASVERMQWKKLQDVHNF PTH (HUMAN) PATHYROID HORMONE (HUMAN, ) PATHYROID HORMONE , HUMAN pTH (human) Acetate(net) Teripatide,PTH ,hPTH ,Human pathyroid hormone PATHYROID HORMONE (PTH) HUMAN , MIN PATHYROID HORMONE HUMAN: FRAGMENT Teripatide acetate H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-g-Val-Glu-Trp-Leu-g-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH acetate salt SVSEIQLMHNLGKHLNSMERVEWKKLQDVHNF CNV-38d Teripatide, Teripatida , Teripatidum [CYS5,28] PTH , HUMAN Teripatide (PTH ) Pathyroid Hormone (PTH) , Human PTH ;HPTH ;HUMAN PATHYROID HORMONE PATHYROID HORMONE FRAGMENT HUMAN APPROX Teriparatide Pteris formosana extract pathyroid hormone fragment human [CYS5,28] PATHYROID HORMONE , HUMAN CNV-38d,Pathyroid Hormone , human C181H291N55O51S2 SER-VAL-SER-GLU-CYS-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-G-VAL-GLU-TRP-LEU-G-LYS-LYS-CYS-GLN-ASP-VAL-HIS-ASN-PHE H-SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-G-VAL-GLU-TRP-LEU-G-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE-OH Teripatide acetate //BP Pth(human) Acetate Teripatida(net) Terlipatide Acetate leripatide acetate Teripatide,PTH ,hPTH ,Human pathyroid hormone SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-G-VAL-GLU-TRP-LEU-G-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE HUMAN Teripatide for system suitability (Y0001895) Path Teripatide D10 AcetateQ: What is Teripatide D10 Acetate Q: What is the CAS Number of Teripatide D10 Acetate Q: What is the storage condition of Teripatide D10 Acetate Q: What e the applications of Teripatide D10 Acetate Teripatide Acetate(free base) Pterospermum heterophyllum Hance HUMAN PATHYROID HORMONE TeripatideAcetateQ: What is TeripatideAcetate Q: What is the CAS Number of TeripatideAcetate Q: What is the storage condition of TeripatideAcetate Q: What e the applications of TeripatideAcetate Teripatide (COLD SHIPMENT REQUIRED) Teropatide hPTH Pathyroid Hormone Fragment Teripatide acetate Powder Teripatide CRS Teripatide (Y0001916) |
| Description | Teriparatide is a PHT agonist, with an IC50 of 2 nM in HEK293 cells. Sequence: Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2 nM (PTH)[1]. |
| In Vivo | Trabecular bone calcium and dry weight of the distal femur increased significantly in Teriparatide-treated animals. The increase in trabecular calcium compared with vehicle control occurred as early as 1 week after initiation of treatment with a 35% and 45% increase, respectively, for 10 μg/kg and 40 μg/kg Teriparatide. Similar results were observed for trabecular dry weight. After 4 weeks of treatment with 10 mg/kg or 40 mg/kg Teriparatide, trabecular calcium increased significantly by 70% and 123%, respectively, compared with the vehicle and by 73%[1]. The 4-week Teriparatide administration increase the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). The 4-week Teriparatide administration + 8-week vehicle administration decrease the pore ratio, number, and density as well as the cortical area and thickness, compared with the 4-week Teriparatide administration, but the pore ratio, cortical area, and thickness are still higher compared with the 12-week vehicle administration. The 4-week Teriparatide administration + 8-week higherdose IBN administration increase the cortical area, thickness, BMC, and volumetricBMD and decrease the pore ratio, but not the pore number or density, compared with the 4-week Teriparatide administration + 8-week vehicle administration[2]. |
| Animal Admin | Rats[1] Teriparatide is administered daily to 4-week-old male rats for 1, 2, or 4 weeks with different concentrations (10, 40 μg/kg). At each time point, longitudinal growth, expressed as maximal femur length, is not statistically different between treated and control rats or between the two different treatment groups. Midfemur diaphyseal widths also do not differ between groups[1]. Rabbits[2] Forty-two female New Zealand white rabbits (17-21 weeks old) are used throughout the study. After 10 days of adaptation to their new environment, the rabbits (18-22 weeks old) are randomized into six groups of 7 animals each using the stratified weight method, as follows: 4-week vehicle administration group (4W-Veh), 4-week Teriparatide (TPTD) administration group (4W-Teriparatide: 20 μg/kg, subcutaneously [s.c.], daily), 12-week vehicle administration group (12W-Veh), 4-week Teriparatide administration + 8-week vehicle administration group (4W-Teriparatide + 8W-Veh), 4-week Teriparatide administration + 8-week lower-dose IBN administration group (4W-Teriparatide + 8W-IBN(L): 20 μg/kg of IBN, s.c., every 4 weeks), and 4-week Teriparatide administration + 8-week higher-dose IBN administration group (4W-Teriparatide + 8W-IBN(H): 100 μg/kg of IBN, s.c., every 4 weeks)[2]. |
| References |
| Molecular Formula | C181H291N55O51S2 |
|---|---|
| Molecular Weight | 4177.77000 |
| Appearance | powder |
| Storage condition | −20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | SQ7770000 |